Stereotactic radiation therapy for recurrent malignant gliomas of the brain: own experience

The purpose of the study was to determine the effectiveness of stereotactic radiation therapy in patients with recurrent malignant gliomas of the brain in dependence on various prognostic factors and to evaluate the effect of temozolomide on overall survival. The study included 46 patients with recurrent malignant gliomas of the brain who received treatment from 2011 to 2018 years in GBUZ “Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine”. The average age of patients was 46,0 ± 12,75 years; the ratio of men and women was 1:1. The relapse of glioblastoma was diagnosed in 24 patients, 22 patients had the relapse of anaplastic astrocytoma. 15 patients received from 4 to 6 cycles of temozolomide monochemotherapy after stereotactic radiation therapy. The median overall survival was 41 months, 1-year overall survival was 97,8%; 3-year overall survival - 52,8%; 5-year overall survival - 35,0%. The median survival after treatment for relapse was 22 months. Main prognostic factors influencing the results of treatment were patients' age, histological characteristics and reoperation. Median overall survival was non-significantly higher in patients with stereotactic radiation therapy and chemotherapy with temozolomide than in patients with stereotactic radiation therapy in a separate version (41 months versus 39 months, p>0,05).